Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States. The company is headquartered in Minneapolis, Minnesota. Show more

2800 CAMPUS DRIVE, MINNEAPOLIS, MN, UNITED STATES, 55441, Minneapolis, MN, 55441, USA

https://www.celcuity.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

4.408B

52 Wk Range

$44.42 - $151.02

Previous Close

$90.08

Open

$88.37

Volume

1,069,434

Day Range

$84.82 - $89.48

Enterprise Value

4.552B

Cash

182M

Avg Qtr Burn

-55.43M

Insider Ownership

10.23%

Institutional Own.

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Gedatolisib + palbociclib + fulvestrant (gedatolisib triplet) Details HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer (ABC)	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Gedatolisib (PKI-587; Revtorpyk) (PI3K/mTOR / PAM pathway inhibitor) Details HR+/HER2-/PIK3CA Mutated Advanced Breast Cancer (ABC)	sNDA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Revtorpyk/Gedatolisib (PKI-587) (PI3K/mTOR Inhibitor) Details HR+/HER2- Locally Advanced Or Metastatic Breast Cancer (Treatment-Naive Advanced Setting)	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Gedatolisib + trastuzumab-pkrb Details HER2+ Metastatic Breast Cancer (mBC)	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Gedatolisib + darolutamide (Nubeqa®) Details Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.